Abcam (ABC)

Sector:

Pharma and Biotech

Index:

FTSE AIM 50

1,304.00p
   
  • Change Today:
    -58.00p
  • 52 Week High: 1,750.00p
  • 52 Week Low: 1,265.00p
  • Currency: UK Pounds
  • Shares Issued: 228.88m
  • Volume: 344,074
  • Market Cap: £2,984.64m
  • RiskGrade: 134

Deal with Barclays    Trade now with Barclays Stockbrokers

Abcam to buy BioVision for $340m

By Michele Maatouk

Date: Monday 02 Aug 2021

LONDON (ShareCast) - (Sharecast News) - Abcam said on Monday that it has agreed to buy California-based BioVision for $340m.
The deal, which is expected to be accretive to earnings from the first full year of ownership after completion, will be funded from existing cash resources and a partial drawdown of Abcam's revolving credit facility.

BioVision, a wholly-owned subsidiary of China's Boai NKY Medical Holdings, is a distributor of life science research tools to biopharma, diagnostic and academic customers. BioVision began supplying Abcam in 2003.

Abcam said its customers' demand for BioVision products has grown consistently over time, with sales more than doubling over the past five years to June 2021.

Abcam CEO Alan Hirzel said: "This acquisition represents a compelling opportunity to secure a proven portfolio of high-quality products, including a leading portfolio of biochemical and cell-based assay kits, that will allow us to better serve customer needs.

"BioVision has sustained strong growth over many years and, together with Abcam's brand, reach and capabilities, we are confident we are well positioned to build on this success and reinforce Abcam's ability to serve life scientists globally."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Abcam Market Data

Currency UK Pounds
Share Price 1,304.00p
Change Today -58.00p
% Change -4.26 %
52 Week High 1,750.00p
52 Week Low 1,265.00p
Volume 344,074
Shares Issued 228.88m
Market Cap £2,984.64m
RiskGrade 134

Abcam Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
76.38% below the market average76.38% below the market average76.38% below the market average76.38% below the market average76.38% below the market average
59.18% below the sector average59.18% below the sector average59.18% below the sector average59.18% below the sector average59.18% below the sector average
Price Trend
34.24% below the market average34.24% below the market average34.24% below the market average34.24% below the market average34.24% below the market average
12.9% below the sector average12.9% below the sector average12.9% below the sector average12.9% below the sector average12.9% below the sector average
Income Not Available
Growth
35.17% above the market average35.17% above the market average35.17% above the market average35.17% above the market average35.17% above the market average
25.71% below the sector average25.71% below the sector average25.71% below the sector average25.71% below the sector average25.71% below the sector average

What The Brokers Say

Strong Buy 3
Buy 1
Neutral 4
Sell 0
Strong Sell 0
Total 8
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Abcam Dividends

  Latest Previous
  Interim Final
Ex-Div 19-Mar-20 07-Nov-19
Paid 17-Apr-20 29-Nov-19
Amount 3.55p 8.58p

Trades for 18-Jan-2022

Time Volume / Share Price
16:35 66,009 @ 1,304.00p
16:29 41 @ 1,305.00p
16:29 150 @ 1,305.00p
16:29 59 @ 1,304.00p
16:29 45 @ 1,304.00p

Abcam Key Personnel

CEO Alan Thomas Hirzel
CFO Michael Baldock

Top of Page